Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.38 |
| ▸ | KLK7 | P49862 | 6/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | RORA | P35398 | 1/20 | 0.34 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19667626 | 0.85 | BRD4 (0.41) | PRKCAKLK7KLK5PRSS1PRSS2 | |
| SCHEMBL19684900 | 0.81 | KCNH2 (0.40) | PRKCAKCNH2SCN9APPARGPPARD | |
| SCHEMBL19684748 | 0.78 | PRKCA (0.36) | PRKCAMEN1KMT2ACNR2 | |
| SCHEMBL19684910 | 0.73 | KLK7 (0.39) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL20873489 | 0.72 | BRD4 (0.43) | PRKCAMEN1KMT2A | |
| SCHEMBL20873490 | 0.72 | BRD4 (0.43) | PRKCAMEN1KMT2A | |
| SCHEMBL19684749 | 0.70 | ALDH1A1 (0.41) | CNR2 | |
| SCHEMBL19684903 | 0.70 | PTK2 (0.37) | PPARGPPARD | |
| SCHEMBL19667670 | 0.67 | KLK7 (0.42) | KLK7 | |
| SCHEMBL23735304 | 0.65 | HSD11B1 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PRKCA 2338/4885KLK7 3842/4885KLK5 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.